BDTX Stock Forecast & Price Target

Black Diamond Therapeutic is a clinical-stage oncology company with a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its silevertinib drug candidate has demonstrated a 60% confirmed objective response rate (cORR) and 86% intracranial cORR in non-small cell lung cancer patients with non-classical EGFR mutations. The company is actively seeking a partner for this program and plans to meet with the FDA in mid-2026 to discuss a potential pivotal trial in 1L NCM EGFR mutations. With a highly attractive entry point and upcoming catalysts for potential value inflection, including clinical data updates and a potential partnership, analysts have a positive outlook for the company's shares.

Black Diamond Therapeutic is a clinical-stage oncology company with a negative outlook due to concerns over their product silevertinib. While the drug has shown promising results in terms of Central Nervous System (CNS) activity, its high toxicity and questions around potential durability raise concerns. The company's planned phase 3 and partnership opportunities also face uncertainty. With a low confidence in their Phase 2 data and questionable developments ahead, a cautious approach is recommended for investors.